TNF and plasma cell myeloma: LEN has shown therapeutic promises in clinical trials for the treatment of multiple myeloma in consideration of its antiangiogenic and anti-inflammatory effects.16, 17, 18, 19, 20 Recently, some treatment strategies for OA are aimed at anti-TNF-α and anti-angiogenesis.42, 43 We expect that treatment with LEN is a potential approach for ameliorating OA.